Fungus-specific CD4+ T cells for rapid identification of invasive pulmonary mold infection

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 3, 2015, Pages 348-352

  Bacher, Petra ^a   Steinbach, Angela ^b,c   Kniemeyer, Olaf ^d,e,f   Hamprecht, Axel ^c   Assenmacher, Mario ^g   Vehreschild, Maria J G T ^b,c   Vehreschild, Jörg J ^b,c   Brakhage, Axel A ^d,e   Cornely, Oliver A ^b,c,h   Scheffold, Alexander ^a,i  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d HANS KNÖLL INSTITUTE   (Germany)

^e FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^f JENA UNIVERSITY HOSPITAL   (Germany)

^g MILTENYI BIOTEC GMBH   (Germany)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ POTSDAM INSTITUTE FOR CLIMATE IMPACT RESEARCH PIK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASPERGILLUS; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; FUNGAL CELL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INVASIVE MOLD INFECTION; LETTER; LUNG MYCOSIS; MUCORALES; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BLOOD; CASE CONTROL STUDY; EARLY DIAGNOSIS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INVASIVE PULMONARY ASPERGILLOSIS; METABOLISM;

ANTIFUNGAL AGENT; BIOLOGICAL MARKER;

ANTIFUNGAL AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; EARLY DIAGNOSIS; HUMANS; IMMUNOCOMPROMISED HOST; INVASIVE PULMONARY ASPERGILLOSIS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 84922309549     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201407-1235LE     Document Type: Letter

References (14)

1. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-653.
2. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008;47:503-509.
3. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Dellow E, Herbrecht R, Donnelly JP. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses 2011;54:e449-e455.
4. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, et al.; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821.
5. Ruhnke M, Böhme A, Buchheidt D, Cornely O, Donhuijsen K, Einsele H, Enzensberger R, Hebart H, Heussel CP, Horger M, et al.; Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology. Diagnosis of invasive fungal infections in hematology and oncology - guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol 2012;23:823-833.
6. Cornely OA, Cuenca-Estrella M, Meis JF, Ullmann AJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. Clin Microbiol Infect 2014;20:1-4.
7. Ostrosky-Zeichner L. Invasive mycoses: diagnostic challenges. Am J Med 2012; 125(1, Suppl)S14-S24.
8. Bacher P, Kniemeyer O, Schönbrunn A, Sawitzki B, Assenmacher M, Rietschel E, Steinbach A, Cornely OA, Brakhage AA, Thiel A, et al. Antigen-specific expansion of human regulatory T cells as a major tolerance mechanism against mucosal fungi. Mucosal Immunol 2014;7:916-928.
9. Bacher P, Schink C, Teutschbein J, Kniemeyer O, Assenmacher M, Brakhage AA, Scheffold A. Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive and memory Th cell repertoire. J Immunol 2013;190:3967-3976.
10. Frentsch M, Arbach O, Kirchhoff D, Moewes B, Worm M, Rothe M, Scheffold A, Thiel A. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med 2005;11:1118-1124.
11. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:427-431.
12. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, Reitsma JB, Bossuyt PM, Vandenbroucke-Grauls CM. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev 2008; (4):CD007394.
13. Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M, Marchetti O; Third European Conference on Infections in Leukemia (ECIL-3). β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 2012;54:633-643.
14. Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9:89-96.